Verma A, Bharti P, Rafat S, Bhatt D, Goyal Y, Pandey K
Oxid Med Cell Longev. 2021; 2021:8832541.
PMID: 33628386
PMC: 7892237.
DOI: 10.1155/2021/8832541.
Bekric D, Neureiter D, Ritter M, Jakab M, Gaisberger M, Pichler M
J Clin Med. 2020; 9(4).
PMID: 32331331
PMC: 7231154.
DOI: 10.3390/jcm9041200.
Upton D, Walters K, Allavena R, Jimenez M, Desai R, Handelsman D
Horm Cancer. 2016; 7(5-6):316-326.
PMID: 27506975
PMC: 10355859.
DOI: 10.1007/s12672-016-0272-3.
Hasima N, Ozpolat B
Cell Death Dis. 2014; 5:e1509.
PMID: 25375374
PMC: 4260725.
DOI: 10.1038/cddis.2014.467.
Chen Z, Li Y, Zhang C, Yi H, Wu C, Wang J
Dig Dis Sci. 2013; 58(10):2887-94.
PMID: 23812859
PMC: 3781302.
DOI: 10.1007/s10620-013-2732-8.
Autophagy as a therapeutic target in cancer.
Chen N, Karantza V
Cancer Biol Ther. 2011; 11(2):157-68.
PMID: 21228626
PMC: 3230307.
DOI: 10.4161/cbt.11.2.14622.
The PEA-15 protein regulates autophagy via activation of JNK.
Bock B, Tagscherer K, Fassl A, Kramer A, Oehme I, Zentgraf H
J Biol Chem. 2010; 285(28):21644-54.
PMID: 20452983
PMC: 2898427.
DOI: 10.1074/jbc.M109.096628.
Role and regulation of autophagy in cancer.
Chen N, Karantza-Wadsworth V
Biochim Biophys Acta. 2009; 1793(9):1516-23.
PMID: 19167434
PMC: 3155287.
DOI: 10.1016/j.bbamcr.2008.12.013.
Genomic structure of chromosome 17 deletions in BRCA1-associated ovarian cancers.
Chisholm K, Goff B, Garcia R, King M, Swisher E
Cancer Genet Cytogenet. 2008; 183(1):41-8.
PMID: 18474296
PMC: 2413294.
DOI: 10.1016/j.cancergencyto.2008.02.004.
Somatic mutations of the PPP2R1B candidate tumor suppressor gene at chromosome 11q23 are infrequent in ovarian carcinomas.
Wu R, Connolly D, Ren X, Fearon E, Cho K
Neoplasia. 2000; 1(4):311-4.
PMID: 10935485
PMC: 1508096.
DOI: 10.1038/sj.neo.7900042.
Evaluation of FHIT gene alterations in ovarian cancer.
Buttitta F, Marchetti A, Radi O, Bertacca G, Pellegrini S, Gadducci A
Br J Cancer. 1998; 77(7):1048-51.
PMID: 9569038
PMC: 2150139.
DOI: 10.1038/bjc.1998.175.
p53 is a persistent and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki67 immunoreactivity.
Rohlke P, Milde-Langosch K, Weyland C, Pichlmeier U, Jonat W, Loning T
J Cancer Res Clin Oncol. 1997; 123(9):496-501.
PMID: 9341899
DOI: 10.1007/BF01192204.
Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3-13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes.
Hatta Y, Takeuchi S, Yokota J, Koeffler H
Br J Cancer. 1997; 75(9):1256-62.
PMID: 9155043
PMC: 2228239.
DOI: 10.1038/bjc.1997.214.
Allele loss from large regions of chromosome 17 is common only in certain histological subtypes of ovarian carcinomas.
Papp J, Csokay B, Bosze P, Zalay Z, Toth J, Ponder B
Br J Cancer. 1996; 74(10):1592-7.
PMID: 8932340
PMC: 2074870.
DOI: 10.1038/bjc.1996.594.
High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci.
Devlin J, Elder P, Gabra H, Steel C, Knowles M
Br J Cancer. 1996; 73(4):420-3.
PMID: 8595153
PMC: 2074458.
DOI: 10.1038/bjc.1996.75.
p53 mutations in cervical carcinogenesis--low frequency and lack of correlation with human papillomavirus status.
Steel C, Williams A, Cohen B, Bird C
Br J Cancer. 1994; 69(4):732-7.
PMID: 8142262
PMC: 1968818.
DOI: 10.1038/bjc.1994.138.
Linkage studies with 17q and 18q markers in a breast/ovarian cancer family.
Milner B, Allan L, Kelly K, Cruickshank D, Hall M, Johnston A
Am J Hum Genet. 1993; 52(4):761-6.
PMID: 8096360
PMC: 1682079.
Interphase molecular cytogenetic analysis of epithelial ovarian carcinomas.
Persons D, Hartmann L, Herath J, Borell T, Cliby W, Keeney G
Am J Pathol. 1993; 142(3):733-41.
PMID: 8096121
PMC: 1886787.
Loss of heterozygosity and amplification on chromosome 11q in human ovarian cancer.
Foulkes W, Campbell I, Stamp G, Trowsdale J
Br J Cancer. 1993; 67(2):268-73.
PMID: 8094291
PMC: 1968175.
DOI: 10.1038/bjc.1993.51.
Alteration of p53 gene in ovarian carcinoma: clinicopathological correlation and prognostic significance.
Niwa K, Itoh M, Murase T, Morishita S, Itoh N, Mori H
Br J Cancer. 1994; 70(6):1191-7.
PMID: 7981076
PMC: 2033683.
DOI: 10.1038/bjc.1994.472.